Hanmi Pharmaceutical

SHAREHOLDER ALERT: Morris Kandinov Investigating HAFC, CVNA, PEGA, and NLTX; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Mercoledì, Agosto 16, 2023
Hanmi, Central District, Hanmi Pharmaceutical, Public sector banks in India, Complaint, District court, Settlement, SAN, Advertising, Carvana

Morris Kandinov is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Hanmi Financial Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Carvana Co. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Pegasystems regarding possible breaches of fiduciary duties and other violations of law on behalf of shareholders.
  • Concerned shareholders are encouraged to contact Leo Kandinov to learn more:
    Morris Kandinov LLP is a national law firm that specializes in recovering investment losses and protecting stockholder rights.

Aptose Reports Results for the Second Quarter 2023

Retrieved on: 
Giovedì, Agosto 10, 2023
CRC, TP53, Investment, APS, Symantec Endpoint Protection, Toronto Stock Exchange, CRH, Mutation, Hanmi Pharmaceutical, Acute myeloid leukemia, MDS, US, AML, Documentation, Patient, Indian stock exchange, CR, FLT3, CRi, TSX, FDA, CRP, US FDA, Pharmaceutical industry, Security (finance)

Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage.

Key Points: 
  • Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage.
  • Equity Investments in Aptose – Today, Aptose announced that it has entered into a binding term sheet with Hanmi Pharmaceutical, Inc. (“Hanmi Pharmaceutical”) of Seoul, South Korea, for an investment of up to $7 million or 19.99 percent ownership interest in Aptose, in two tranches.
  • A monotherapy recommended Phase 2 dose of 80 mg daily was selected and all tuspetinib development paths remain open, including the single arm accelerated path.
  • Plan to discuss strategies for potential future monotherapy accelerated development, doublet phase 2 development, and triplet pilot development (4Q 2023)

Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Martedì, Maggio 9, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Workforce, CVR, Quarter, Marketing, Continuous operation, Spectrum Pharmaceuticals, Research, Medication, Acquisition, Patient, Injection, Hanmi Pharmaceutical, SPPI, Growth, Assertio Therapeutics, FDA, Spectrum, Pharmaceutical industry, Video game, Cryptocurrency

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.

Key Points: 
  • Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a commercial stage biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended March 31, 2023, and provided a corporate update.
  • 172 targeted accounts purchased ROLVEDON™ (eflapegrastim-xnst) Injection during the quarter compared to 70 in Q4 2022, an increase of 145%.
  • “Spectrum delivered a strong start to 2023 with outstanding execution in the launch of ROLVEDON.
  • The Company had a total cash, cash equivalents, and marketable securities balance of approximately $56.1 million as of March 31, 2023.

Hanmi Pharmaceutical's Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirmed Non-inferiority Efficacy and Safety Compared to Monotherapy in 'The Lancet' & 'European Heart Journal'

Retrieved on: 
Venerdì, Marzo 17, 2023
Atherosclerosis, European Heart Journal, Hanmi Pharmaceutical, Diabetes, Dyslipidemia, DM, Ezetimibe, Clinical trial, Record, Patient, ASCVD, Ezetimibe/rosuvastatin, The Lancet, Pharmaceutical industry

R&D-oriented pharmaceutical company, Hanmi Pharmaceutical's Rosuzet is a dyslipidemia medicine, is a single-pill combination of two different active ingredients: rosuvastatin and ezetimibe, and is a blockbuster product that records prescription sales in Korea of more than one hundred million dollars.

Key Points: 
  • R&D-oriented pharmaceutical company, Hanmi Pharmaceutical's Rosuzet is a dyslipidemia medicine, is a single-pill combination of two different active ingredients: rosuvastatin and ezetimibe, and is a blockbuster product that records prescription sales in Korea of more than one hundred million dollars.
  • The result of a large randomized trial comparing Rosuzet and rosuvastatin monotherapy in 3,780 patients with arteriosclerotic cardiovascular disease (ASCVD) was published in The Lancet(IF 202.731) in August, 2022.
  • A sub-analysis of the diabetes mellitus (DM) cohort of the RACING study was published in the European Heart Journal(IF 35.855) in December, 2022.
  • This study evaluated the effect of moderate-intensity statin with ezetimibe combination therapy(Rosuzet) versus high-intensity statin monotherapy among 1398 patients with DM and ASCVD.

Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting

Retrieved on: 
Giovedì, Settembre 22, 2022
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, SPPI, Safety, Poziotinib, Nasdaq, Hanmi Pharmaceutical, FDA, Food, Stomach, Spectrum Pharmaceuticals, Quality control, Hanmi, Company, 8-K, Review, HER2, PDUFA, U.S. Securities and Exchange Commission, Program, Patient, Lung cancer, Cancer, Breast cancer, ODAC, Broadcast license, HER4, Annual report, Medication, TKI, Private Securities Litigation Reform Act, Security (finance), Large-cell lung carcinoma, SEC, EGFR, Pharmaceutical industry, NSCLC, Spectrum

The committee makes appropriate recommendations to the FDA, but these recommendations are not binding and the final decision regarding product approval will be made solely by the FDA.

Key Points: 
  • The committee makes appropriate recommendations to the FDA, but these recommendations are not binding and the final decision regarding product approval will be made solely by the FDA.
  • Spectrum Pharmaceuticals holds an exclusive license from Hanmi Pharmaceutical (Hamni) to develop, manufacture, and commercialize poziotinib worldwide, excluding Korea and China.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022

Retrieved on: 
Sabato, Settembre 10, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, U.S. Securities and Exchange Commission, Stomach, Nasdaq, Assistant professor, Population, SPPI, 8-K, Cohort, Breast cancer, Mutation, AES, University, Neoplasm, BID, TKI, DOR, Spectrum Pharmaceuticals, FDA, EGFR, Large-cell lung carcinoma, C2, Cancer, ORR, Private Securities Litigation Reform Act, SEC, European Society for Medical Oncology, Medication, MD Anderson Cancer Center, Broadcast license, Investor relations, ESMO, HER2, Hanmi Pharmaceutical, Patient, Quality control, Overalls, HER4, Poster, Security (finance), Annual report, Pharmaceutical industry, NSCLC, Spectrum, C4

The data show that poziotinib is highly active in G778 mutations in both treatment nave and previously treated patients with NSCLC.

Key Points: 
  • The data show that poziotinib is highly active in G778 mutations in both treatment nave and previously treated patients with NSCLC.
  • A poster with the data is available to registered participants at the European Society for Medical Oncology Congress (ESMO) 2022 taking place in Paris from September 9-13, 2022.
  • The G778 mutation is one of the frequent HER2 exon 20 insertion mutations and patients with these tumors have a poor prognosis, said Francois Lebel, M.D., Chief Medical Officer of Spectrum Pharmaceuticals.
  • There is no approved therapy specifically for either treatment-nave or previously treated NSCLC with HER2 exon 20 insertion mutations.

Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

Retrieved on: 
Venerdì, Settembre 9, 2022
Biotechnology, FDA, Health, Pharmaceutical, Oncology, Spectrum Pharmaceuticals, Hanmi Pharmaceutical, Incidence, Neutropenia, Medication, Febrile neutropenia, Pegfilgrastim, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Adult, DSN, Nasdaq, Infection, SPPI, Senior, Food, FDA, BLA, Hematopoietic stem cell transplantation, Patient, Pharmaceutical industry, Spectrum

Our commercial team is in place and ready to engage key stakeholders immediately, said Erin Miller, Senior Vice President, Sales & Marketing of Spectrum Pharmaceuticals.

Key Points: 
  • Our commercial team is in place and ready to engage key stakeholders immediately, said Erin Miller, Senior Vice President, Sales & Marketing of Spectrum Pharmaceuticals.
  • ROLVEDON (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation.
  • SPECTRUM PHARMACEUTICALS, INC. is a registered trademark of Spectrum Pharmaceuticals, Inc. and its affiliates.
  • REDEFINING CANCER CARE and ROLVEDON are the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022

Retrieved on: 
Lunedì, Settembre 5, 2022
Pharmaceutical, Health, Oncology, Biometrics, Spectrum, Breast cancer, EGFR, Security (finance), Division, Hanmi Pharmaceutical, Stomach, Large-cell lung carcinoma, Internal medicine, Nasdaq, Medication, Poster, MD Anderson Cancer Center, Humanitarian use licenses, SPPI, ESMO, Department, University, Investor relations, U.S. Securities and Exchange Commission, TKI, Spectrum Pharmaceuticals, HER2, FDA, Cancer, Quality control, HER4, Assistant professor, Pharmaceutical industry, NSCLC

The poster will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2022 that will take place in Paris from September 9-13, 2022.

Key Points: 
  • The poster will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2022 that will take place in Paris from September 9-13, 2022.
  • HER2 exon 20 insertion mutations are a rare subset accounting for approximately 2-4% in NSCLC.
  • There is no approved therapy specifically for either treatment-nave or previously treated NSCLC with HER2 exon 20 insertion mutations.
  • REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Standigm names Carl Foster chief business officer to expand strategic partnerships for AI drug discovery

Retrieved on: 
Giovedì, Agosto 18, 2022
Antibody, Genomics, University, M. Levin & Co, Inc, Merck Group, Parkinson's disease, Multimedia, Hanmi Pharmaceutical, Drug discovery, CEO, Insilico Medicine, Technology, Degenerative disease, Research, Merck, Probability, Proteomics, Marketing, NASH, SK Group, Oracle, Partnership, Automation, Foster, Workflow, Biochemistry, MBA, Autism, Solution, Efficiency, Pharmaceutical industry, Management, Medical device, AI

SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the appointment of Chief Business Officer Carl Foster. Based in our U.S. office, Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications.

Key Points: 
  • SEOUL, South Korea, Aug. 18, 2022 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the appointment of Chief Business Officer Carl Foster.
  • Based in our U.S. office,Foster will be responsible for expanding strategic partnerships for novel drug target discoveries and first-in-class lead candidate identifications.
  • Founded in 2015, Standigm has established an early-stage drug discovery workflow AI to generate multiple First-in-Class compounds within average seven months.
  • Pursuing full-stack, AI-driven industrializing drug discovery, Standigm has achieved the automation of molecular design workflow, and the automation effort has been expanding to the whole drug discovery process based on Standigm AI platforms, including Standigm ASK for novel target discovery, Standigm BEST for novel compound generation and Standigm Insight for novel indication.

KT Corporation and Hanmi Pharmaceutical promote business cooperation with Digital Pharm, a Korean company specializing in digital treatment devices and electronic drugs

Retrieved on: 
Martedì, Giugno 21, 2022
Dai, Cloud, Digital, CNS, US Foods, Agriculture, FDA, Therapy, Drug development, US, Telecommunication, Food and Drug Administration, Technology, KT Corporation, Single-frequency network, Dysphagia, Depression, Biotechnology, Catholic higher education, Epilepsy, Hearing loss, Heart, Professor, Investment, Lists of diseases, Intention, Robot, Catholic (term), Big data, Hanmi Pharmaceutical, Partnership, ADHD, Hanmi, Food, ICT, Attention deficit hyperactivity disorder, AI, Monarch, Anticonvulsant, Telephony, Digital health, Nicotine, GLOBE, Pharmaceutical industry, Mobile phone, KT

KT and Hanmi Pharmaceutical to jointly invest in Digital Pharm, a company specializing in digital treatment devices and electronic drugs

Key Points: 
  • KT and Hanmi Pharmaceutical to jointly invest in Digital Pharm, a company specializing in digital treatment devices and electronic drugs
    SEOUL, South Korea, June 20, 2022 (GLOBE NEWSWIRE) -- Digital platform company KT Corporation (CEO Koo Hyun-mo; www.kt.com) and Hanmi Pharmaceutical (CEO Woo Jong-su, Kwon Se-chang), a pharmaceutical company specializing in R&D-focused new drug development, have co-invested in Digital Pharm, a company specializing in DTx and electroceuticals.
  • The companies announced on June 19, 2022 that KT and Hanmi completed their investments in Digital Pharm and held a launch ceremony.
  • In the future, KT plans to develop a digital treatment platform, establish business strategies for the new company, and build a pipeline of digital treatment devices and electroceuticals.
  • Hanmi will establish digital therapeutics B2H (business to hospital) and sales and marketing strategies to activate the nascent digital therapeutics prescription market.